Received Apr 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | TS525 | — |
Second dose 5 years after first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 70-year-old female patient who received Herpes zoster (Shingrix) (batch number TS525, expiry date 10-MAR-2027) for prophylaxis. Previously administered products included Shingrix (the first dose was given 5 years ago). On 21-APR-2025, the patient received the 2nd dose of Shingrix. On 21-APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Second dose 5 years after first dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 20-APR-2025 Other HCP reported that pharmacist mentioned that on the day of reporting, a patient received the second dose of Shingrix. However, the first dose was given 5 years ago. Reporter asked if the patient should received a booster dose. Consented to follow up. The patient received 2nd dose of Shingrix,?later than the recommended interval, which led to lengthening of vaccinations schedule.